CLINICAL TRIAL / NCT04803058
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
- Interventional
- Recruiting
- NCT04803058
Contact Information
A Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-Myeloablative Conditioning, Including Fludarabine and Cyclophosphamide, for Tolerance Induction in Living Donor Renal Transplantation
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients